About

Okogen is an ophthalmic specialty pharmaceutical company focused on developing innovative therapies to treat diseases of the eye. We focus on addressing the underlying cause of these diseases rather than treating their symptoms. Our lead product candidate, OKG-0301, is being developed to treat viral conjunctivitis (also known as pink eye), a viral infection that affects approximately 30 million people worldwide each year and for which there are no approved therapies.

Leadership

Okogen’s management team, board of directors and strategic advisors comprise biotechnology executives with ophthalmic experience and a track record of commercial success.


Management

Brian M Strem, PhD 

Brian M Strem, PhD is a co-founder and the CEO of Okogen Inc. Prior to founding Okogen, Brian worked at Sound Pharmaceuticals, Allergan and Shire, responsible for business development and corporate strategy in ophthalmology, otology and regenerative medicine. Brian began his career at Cytori Therapeutics with elevating roles within the commercial and R&D departments.


Eric Daniels, MD, MBA

Eric Daniels, MD, MBA is a Co-Founder and the Chief Operating Officer of Okogen. Eric has nearly 20 years of operating experience in biotechnology and medtech companies, including Tensys Medical, Kerastem, and Cytori Therapeutics, where he has held leadership roles within the commercial, medical and R&D organizations. Dr. Daniels holds a Masters of Business Administration from the Anderson School of Management at the University of California, Los Angeles. Dr. Daniels received his Doctor of Medicine degree from the University of California, Los Angeles School of Medicine and his undergraduate degree in Molecular Biology from the University of California, Berkeley.


Board Of Directors

Brad Conlan

Brad Conlan is the co-founder of Bimini Technologies and has served as company’s CEO since 2013 and has worked in the medical device and biologic space for over 15 years.  Bimini’s holdings include multiple medical device platforms and biologic candidates. Prior to Bimini, Brad worked with Cytori Therapeutics where he served as the Company’s Director of Global Marketing as well as head of the Regenerative Medicine Business Unit. During his time at Cytori, Brad was directly responsible for the research and development of the Celution Cell Therapy platform and managed cross functional teams that drove the products from concept to commercialization.


Quinton Oswald

Quinton Oswald is the CEO of Notal Vision, a cloud based telemedicine company driven by AI tools. Most recently, he served as CEO of Neurotech and prior to that, CEO of SARcode Bioscience, where he was instrumental in the clinical development of lifitegrast ophthalmic solution 5% (Xiidra™) for the treatment of dry eye disease (sold to Shire, PLC). Previously, he was Vice President & Business Unit Head for Genentech’s Tissue Growth and Repair Business, where he also oversaw the highly successful commercial launch of Lucentis® (ranibizumab) for the treatment of wet AMD. Prior to Genentech, Quinton led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD.


Leighton Read

Leighton Read, MD is a serial entrepreneur and venture investor with a long track record of building companies that have commercialised important medicines and life-science technologies.  From 2000 – 2008 he was a managing director of Alloy Ventures, an early-stage firm investing in life science and technology companies. Previously, he founded Affymax NV (sold to GSK) and spun out Affymetrix and Maxygen.  He was the founding investor, Chairman and CEO of Aviron which developed FluMist™, the intranasal influenza vaccine (acquired by MedImmune). Leighton serves as a trustee or director of The BeneTech Initiative, BioVentures for Global Health, The UC Berkeley Foundation and School of Public Health Council, and is Vice Chairman of the Santa Fe Institute.



Chris Smith, PhD, MBA

Chris Smith, PhD, MBA is a Senior Investment Manager at Brandon Capital Partners, Australia’s largest life-science VC. Before this Chris was a Business Development Manager with CSL Ltd, Australia’s largest pharmaceutical company and one of the top 10 biotechnology companies in the world. At CSL Chris was responsible for identifying and reviewing opportunities for CSL’s global R&D pipeline. Chris spent three years as a postdoctoral immunologist and virologist at The University of Cambridge, UK.


Brian M Strem, PhD 

Brian M Strem, PhD is a co-founder and the CEO of Okogen Inc. Prior to founding Okogen, Brian worked at Sound Pharmaceuticals, Allergan and Shire, responsible for business development and corporate strategy in ophthalmology, otology and regenerative medicine. Brian began his career at Cytori Therapeutics with elevating roles within the commercial and R&D departments.